1. Toal C. B., Meredith P.A., Elliott H.L. Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: A literature review comparing amlodipine and nifedipine GITS. Blood Pressure 2012; 21 (Suppl 1): 3–10
2. Dahlof B, Sever PS, Poulter NR, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.
3. Dolan EA, Stanton AVB, Parker KH, et al. on behalh of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts caediovascular events in treated hypertensive patients – ASCOT substudy. J Hypertens 2009; 27: 876–85.
4. Rothwell PM, Howard SC, Dolan E, et al.; on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of b-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469–80.
5. Staessen J.A., Birkenha W.H.VALUE: to the heart of the matter. J Hypertens 2004; 22(8):1431–1434.
6. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981–97.
7. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217–26.
8. The CAFE investigators, for the ASCOT investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the conduit artery evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
9. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, et al.Predictors of Antihypertensive Drug Responses: Initial Data from a Placebo-Controlled, Randomized,Cross-Over Study With Four Antihypertensive Drugs (The GENRES Study). AJH 2007; 20:311–318.
10. Chazova I.E, Karpov Y.A., Vigdorchik A.V. on behalf of research group. Efficacy and safety of amlodipine
11. and valsartan single pill combination in treatment of arterial hypertension in real life practice: results of the Russian observational study EXTRA. Sistemnye Gipertenzii 2010; (2): 18–26. Russian (Чазова И.Е., Карпов Ю.А., Вигдорчик А.В. от лица исследовательской группы. Эффективность и безопасность комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: первые результаты российского наблюдательного исследования ЭКСТРА-2. Системные Гипертензии 2010; (2): 18–26).
12. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the rogression of atherosclerosis and the occurrence of clinical events. REVENT Investigators. Circulation 2000;102:1503–10.
13. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217–26.
14. Hernandez R, Carvajal AR, Armas-de Hernandez MJ et al. Effects of amlodipine on platelet aggregation and blood pressure in patients with essential hypertension. Clin Ther 1993;15(2):304–13.
15. Morgan T, Anderson A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens (Greenwich) 2003;5(1): 53–7.
